← Back to headlines
Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
Alnylam Pharmaceuticals has reported a target of $3 billion in revenue for 2025, driven by a 151% surge in its TTR franchise.
20 Feb, 09:08 — 20 Feb, 09:08
Sources
Showing 1 of 1 sources
